A major diagnostics firm conducts global business development and licensing in early stage diagnostic and sequencing technologies. The firm employs a variety of deal structures including IP rights, co-development, partnerships, and M&A.
The firm is interested in new technologies in point of care diagnostics, molecular diagnostics, tissue diagnostics, bioinformatics, and instrumentation, sequencing and associated software. The firm’s indications of interest include oncology, sepsis, pre-natal health and women’s health, bone metabolism, cardiovascular disease, diabetes and metabolic disease, kidney disease, infectious disease, and genetic disorders.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com





Leave a comment